阅读说明：本技术 一种治疗或缓解带刺突蛋白的球形病毒引起的疾病的方法 (A method for treating or relieving diseases caused by Spodovirus with spike protein ) 是由 于毅欣 于 2021-08-22 设计创作，主要内容包括：一种治疗或缓解带刺突蛋白的球形病毒引起的疾病的方法,其特征在于,包括：判断患者的疾病是一种带刺突蛋白的球形病毒所引起的；给患者注射一种已有的带刺突蛋白的球形病毒的减毒活疫苗；在一周到二十周后或已经产生此减毒活疫苗的病毒抗体后注射此减毒活疫苗对应的病毒。本发明只要确定患者的疾病是由一种带刺突蛋白的球形病毒所引起的情况下,从已有减毒活疫苗中找到带刺突蛋白的球形病毒的减毒活疫苗来给患者注射,待患者能够产生对此减毒活疫苗的病毒的抗体之后,再对此患者注射此减毒活疫苗的病毒,利用此减毒活疫苗的病毒的抗体来治疗暂时没有疫苗的新病毒或某种带刺突蛋白的球形病毒所引起的疾病。(A method of treating or ameliorating a disease caused by a spike protein bearing orbivirus comprising: judging the disease of the patient is caused by a globular virus with spike protein; injecting the patient with an existing live attenuated vaccine of the globular virus with spike protein; the virus corresponding to the live attenuated vaccine is injected after one to twenty weeks or after the virus antibodies of the live attenuated vaccine have been produced. The invention only needs to determine that the disease of the patient is caused by a spherical virus with spike protein, finds the attenuated live vaccine of the spherical virus with spike protein from the existing attenuated live vaccines to inject the vaccine to the patient, and injects the virus of the attenuated live vaccine to the patient after the patient can generate the antibody of the virus of the attenuated live vaccine, and uses the antibody of the virus of the attenuated live vaccine to treat the disease caused by a new virus without vaccine or a spherical virus with spike protein.)

1. A method of treating or ameliorating a disease caused by a spike protein bearing orbivirus comprising:

judging the disease of the patient is caused by a globular virus with spike protein;

injecting the patient with an existing live attenuated vaccine of the globular virus with spike protein;

the virus corresponding to the live attenuated vaccine is injected after one to twenty weeks or after the virus antibodies of the live attenuated vaccine have been produced.

Technical Field

The invention relates to the technical field of medical treatment, in particular to a method for treating or relieving diseases caused by a globular virus with spike protein.

Background

Sometimes new viruses appear without a temporarily effective vaccine or specific drug or treatment. The invention only needs to determine that the disease of the patient is caused by a spherical virus with spike protein, finds the attenuated live vaccine of the spherical virus with spike protein from the existing attenuated live vaccines to inject the vaccine to the patient, and injects the virus of the attenuated live vaccine to the patient after the patient can generate the antibody of the virus of the attenuated live vaccine, and uses the antibody of the virus of the attenuated live vaccine to treat the disease caused by a new virus without vaccine or a spherical virus with spike protein. One feature of the present invention is that the method of the present invention can be used without using an electron microscope of extremely high precision to determine the size of spike protein of a globular virus, and only by determining that a patient is infected with a globular virus having spike protein.

Disclosure of Invention

According to one aspect of the present disclosure, a method for treating or ameliorating a disease caused by a spike protein-bearing orbivirus, comprising:

judging the disease of the patient is caused by a globular virus with spike protein;

injecting the patient with an existing live attenuated vaccine of the globular virus with spike protein;

the virus corresponding to the live attenuated vaccine is injected after one to twenty weeks or after the virus antibodies of the live attenuated vaccine have been produced.

Preferably, as an alternative embodiment, the time interval for injecting the virus corresponding to the live attenuated vaccine may be once in 1 to 35 days until the symptoms caused by the new virus disappear or disappear completely.

Preferably, as an alternative embodiment, the virus corresponding to the live attenuated vaccine can be injected after detecting the presence of antibodies against the virus corresponding to the live attenuated vaccine.

Preferably, as an alternative embodiment, 1mg to 100mg of the zinc-containing compound may be taken daily to improve immunity.

Preferably, as an alternative embodiment, 1mg to 5000mg of the phosphorus-containing compound may be administered daily to enhance immunity.

Preferably, as an alternative embodiment, during the onset period of the live attenuated vaccine, i.e. when the virus antibodies corresponding to the live attenuated vaccine can be generated, if the new virus is obtained, the virus corresponding to the live attenuated vaccine can be directly injected to obtain the virus antibodies corresponding to the live attenuated vaccine.

Further, the effective period refers to a period during which antibodies can be produced against the virus corresponding to the live attenuated vaccine.

Further, for example, when measles vaccine is injected, new coronary pneumonia is acquired after one year, and the body can still produce antibodies of measles vaccine, measles vaccine virus is directly injected without additional measles vaccine injection.

Preferably, as an alternative embodiment, in selecting the species of live attenuated vaccine, the virus species that are less symptomatic at onset are selected as much as possible.

Preferably, the dose of injected virus is estimated based on the physical condition and medical history of the patient, and can be injected gradually or in a dose of 0.001 to 1 ten thousand times the viral load of the attenuated live vaccine.

Detailed Description

The following examples are intended to illustrate the invention but are not intended to limit the scope of the invention.

Example 1

The method comprises the following steps: first, it was determined that a patient had acquired a new coronavirus.

Step two: a new patient with measles virus infected with measles virus was injected with live measles attenuated vaccine.

Step three: after confirming that the patient was able to produce measles virus antibodies two weeks later, the patient was injected with measles virus.

Step four: after two weeks the measles virus was injected again if there were still new symptoms of coronary pneumonia or if the new coronary pneumonia test was positive.

Step five: after two weeks the measles virus was injected again if there were still new symptoms of coronary pneumonia or if the new coronary pneumonia test was positive.

The above is a specific embodiment of the present invention, but the scope of the present invention should not be limited thereto. Any changes or substitutions that can be easily made by those skilled in the art within the technical scope of the present invention are included in the protection scope of the present invention, and therefore, the protection scope of the present invention is subject to the protection scope defined by the appended claims.